里昂：和黄医药赛沃替尼研究数据向好 维持“跑赢大市”评级

Core Viewpoint - The latest research results for Savolitinib and Osimertinib combination therapy for non-small cell lung cancer from Hutchison China MediTech were positively received, indicating good efficacy and safety [1] Group 1: Clinical Trial Results - The mid-term analysis shows that the combination therapy of Savolitinib and Osimertinib demonstrates significant efficacy compared to the control group [1] - Management noted that the overall survival trend is positive but not yet mature [1] Group 2: Market Implications - The new research data is expected to facilitate the expansion of Savolitinib's indications in China [1] - Citi maintains a "Outperform" rating for Hutchison China MediTech with a target price of HKD 30.7 [1]